Caris Life Sciences, Inc. (CAI)
14.55
-0.70
(-4.59%)
USD |
NASDAQ |
May 15, 16:00
14.75
+0.20
(+1.37%)
After-Hours: 20:00
Caris Life Sciences EPS Diluted (Quarterly) : -0.0018 for March 31, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Neurocrine Biosciences, Inc. | 1.914 |
| Nuvalent, Inc. | -1.389 |
| Alnylam Pharmaceuticals, Inc. | 1.508 |
| Glaukos Corp. | -0.341 |
| CytomX Therapeutics, Inc. | -0.1029 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -0.51M |
| Revenue (Quarterly) | 216.17M |
| Total Expenses (Quarterly) | 216.68M |
| Enterprise Value | 3.713B |
| Gross Profit Margin (Quarterly) | 65.39% |
| Profit Margin (Quarterly) | -0.24% |
| Earnings Yield | -10.07% |
| Operating Earnings Yield | 2.64% |
| Normalized Earnings Yield | -9.390 |